Hyperleukocytosis Detected
WBC >100,000/µL in setting of leukemia
All Pathways
Hematology & OncologyEmergency
Hyperleukocytosis and Leukostasis Management (ATS 2025)
Hyperleukocytosis and Leukostasis Management (ATS 2025): Hyperleukocytosis Detected → Leukemia Type → Screen for Leukostasis Symptoms → Symptomatic Leuk...
Pathway Overview
13 steps
Algorithm Steps
13 total
01Start 02Decision Leukemia Type
AML/CML blast crisis vs ALL/CLL
- AML: Highest risk of leukostasis (15-20% mortality)
- CML blast crisis: High risk
- ALL: Lower risk but can occur
- CLL: Very rare to cause leukostasis despite high counts
03Action Screen for Leukostasis Symptoms
End-organ manifestations
- Pulmonary: Dyspnea, hypoxia, diffuse infiltrates
- CNS: Confusion, headache, visual changes, stroke
- Hemorrhage: Retinal, pulmonary, CNS
- Note: Leukostasis can occur at WBC <100k
- Cell type more predictive than count
04Decision Symptomatic Leukostasis?
Respiratory or neurological symptoms
05Warning SYMPTOMATIC - Emergency
Immediate intervention required
- ICU admission
- Supplemental oxygen
- AVOID RBC transfusion if possible (increases viscosity)
- Consider mechanical ventilation if severe
06Action Tumor Lysis Syndrome Prevention
Critical with cytoreduction
- Aggressive IV hydration 2-3 L/day
- Allopurinol 300-600mg daily, OR
- Rasburicase 0.2mg/kg if high uric acid (avoid in G6PD)
- Monitor electrolytes, uric acid, creatinine q6h
- Avoid potassium in IV fluids initially
07Action Cytoreduction
Reduce WBC count rapidly
- Hydroxyurea 50-100 mg/kg/day in divided doses
- Can give up to 10g/day in emergency
- Low-dose cytarabine as alternative
- Definitive chemotherapy once diagnosis confirmed
- Hematology/oncology consultation
08Decision Consider Leukapheresis?
Controversial - not routine
- May be considered if:
- - Symptomatic leukostasis
- - Unable to tolerate chemotherapy
- - Bridge to definitive treatment
- NOT routinely recommended
- AVOID in APL
09Action Proceed with Leukapheresis
If available and indicated
- Removes 30-60% WBC per session
- May need daily sessions
- Temporary measure only
- Continue hydroxyurea concurrently
10Action Monitoring
Frequent reassessment
- CBC q6-12h initially
- Electrolytes, uric acid q6h
- Continuous pulse oximetry
- Neurologic checks
- Target WBC <50-100k before definitive chemo
11Outcome Leukostasis Managed
Transition to definitive leukemia treatment
12Action Medical Management Only
Continue cytoreduction and supportive care
- Path rejoins step 10Shared downstream outcome
13Action Asymptomatic Hyperleukocytosis
Preventive management
- High risk of developing leukostasis
- Monitor closely in hospital
- Proceed with cytoreduction
- Path rejoins step 06Shared downstream outcome
Guideline Source
Management of Leukostasis in Acute Myeloid Leukemia
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- WBC count alone does not predict leukostasis - cell type matters
- Leukapheresis role is controversial and institution-dependent
- Avoid RBC transfusion unless symptomatic anemia - increases viscosity
- APL with leukostasis requires different management
Applicable Regions
USEUGlobal
US: Leukapheresis availability varies by center
Global: Hydroxyurea universally available
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Absolute Neutrophil Count (ANC)
Absolute neutrophil count from CBC for neutropenia grading
Open page
Compare
AttendMe.ai vs OpenEvidence
See how this pathway workflow compares against OpenEvidence.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the Hyperleukocytosis and Leukostasis Management (ATS 2025)?
The Hyperleukocytosis and Leukostasis Management (ATS 2025) is a emergency clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on Management of Leukostasis in Acute Myeloid Leukemia.
What guideline is the Hyperleukocytosis and Leukostasis Management (ATS 2025) based on?
This algorithm is based on Management of Leukostasis in Acute Myeloid Leukemia (DOI: 10.34197/ats-scholar.2025-0039OT).
What are the limitations of the Hyperleukocytosis and Leukostasis Management (ATS 2025)?
Known limitations include: WBC count alone does not predict leukostasis - cell type matters; Leukapheresis role is controversial and institution-dependent; Avoid RBC transfusion unless symptomatic anemia - increases viscosity; APL with leukostasis requires different management. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Hyperleukocytosis and Leukostasis Management (ATS 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free